ArticleBasic and clinical andrology2025
Male polycystic ovarian syndrome phenotype: a meta-analysis of endocrine-metabolic dysregulation in fathers and brothers of PCOS-affected women.
Article in Basic and clinical andrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a common endocrine disorder in women with potential familial and genetic components. Emerging evidence suggests that male first-degree relatives (fathers and brothers) may exhibit endocrine and metabolic abnormalities similar to a "male equivalent" of PCOS, although the condition remains without clear diagnostic criteria. We conducted a systematic review and meta-analysis to investigate whether male relatives of women with PCOS show consistent patterns of metabolic and hormonal dysregulation.
resultsA total of 21 studies met inclusion criteria, encompassing male first-degree relatives of women with PCOS with available data on metabolic, hormonal, and cardiovascular outcomes. Meta-analysis showed that male relatives had significantly higher fasting blood glucose (MD: 6.25; 95% CI: 1.36-11.14), body mass index (1.18; 0.35-2.02), triglycerides (17.82; 10.82-24.81), total cholesterol (18.63; 6.16-31.10), LDL-cholesterol (12.99; 1.27-24.71), and dehydroepiandrosterone sulfate (1.29; 0.66-1.92) compared with controls. They also exhibited higher prevalence of hypertension (OR: 1.88; 1.18-2.29), waist circumference > 90 cm (3.27; 1.18-9.08), and androgenetic alopecia (1.65; 1.04-2.60). Findings were consistent across studies, with low to moderate heterogeneity and minimal publication bias.
conclusionMale first-degree relatives of women with PCOS demonstrate increased rates of metabolic abnormalities, hormonal imbalances, and androgenic features, supporting the concept of a male PCOS of equivalent. These findings underscore the familial nature of PCOS and highlight the need for improved diagnostic criteria and higher clinical awareness. Screening male relatives for metabolic and hormonal risk factors may help identify at-risk individuals and inform preventive interventions.
trial registrationIR.SBMU.ENDOCRINE.REC.1403.146.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.